MGI Tech’s DNBSEQ-E25 Receives NMPA License as World’s First Self-Luminescent Sequencer
China-based gene sequencing specialist MGI Tech Co., Ltd has announced that it has received a...
Medtronic’s BrainSense Technologies Win EU, UK CE Mark for Parkinson’s Treatment
US-Irish firm Medtronic (NYSE: MDT) has announced that it has received CE (Conformité Européenne) Mark...
Sansure Biotech to Acquire Sinobioway Hygene for $110M to Boost Product Pipeline
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced plans to acquire 100%...
Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative...
Merck’s Keytruda Gains NMPA Approval for HNSCC Indication in China
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced that it has received...
Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Zhaoke Ophthalmology Partners with AFT for Brimochol PF Distribution in ANZ
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a strategic distribution and supply agreement with...
Tonghua Dongbao Begins Phase II Trial for GLP-1/GIP Agonist THDBH120 in Weight Loss
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced a significant milestone in its clinical development...
Neo Modulus Secures $40.9M Series C Funding for Regenerative Medical Devices
Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd., a prominent developer of regenerative implantable medical devices...
MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors
Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...
Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500
China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...
CSPC’s Prusogliptin Approved in China for Type 2 Diabetes Treatment
China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co.,...
3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303
China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...
CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion
CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in...
JW Therapeutics’ Carteyva Granted Breakthrough Therapy Designation by CDE
China-based JW Therapeutics (HKG: 2126) has announced that its Carteyva (relmacabtagene autoleucel injection) has been...
CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...
Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership
China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...
Johnson & Johnson MedTech’s Dual Energy Catheter Gains CE Mark
US major Johnson & Johnson MedTech has announced that its Dual Energy THERMOCOOL SMARTTOUCH SF...
Henlius Biotech Gains NMPA Clearance for HLX43 ADC Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clearance from...
Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development
China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal...